UroGen Pharma Ltd

UroGen Pharma Ltd

URGN

Get informed when a big investor buys or sells

+ Follow
Market Cap$1.86B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
UroGen Pharma LtdUroGen Pharma Ltd-13.9-107%20-1.7
$44.20

Target Price by Analysts

10.7% upsideUroGen Pharma Target Price DetailsTarget Price
$-30.93

Current Fair Value

177.5% downside

Overvalued by 177.5% based on the discounted cash flow analysis.

Share Statistics

Market cap$1.86 Billion
Enterprise Value$1.96 Billion
Dividend Yield$- (-)
Earnings per Share$-3.19
Beta1.58
Outstanding Shares50,182,758

Return

Return on Equity107.22%ROE
Return on Assets-52.51%
Return on Invested Capital-55.46%

Valuation & Multiples

P/E Ratio-13.91P/E Ratio
PEG30.08PEG
Price to Sales19.96Price to Sales
Price to Book Ratio-13.31Price to Book Ratio
Enterprise Value to Revenue13.93
Enterprise Value to EBIT-17.38
Enterprise Value to Net Income-15
Total Debt to Enterprise0.1
Debt to Equity-1.65Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
May 11, 2026
EPS Estimate
$-0.48
Average shareholder expectation
Revenue Estimate
$44.83 M
Average shareholder expectation

Next Earnings Call

Expected Date
August 5, 2026
EPS Estimate
$-0.27
Average shareholder expectation
Revenue Estimate
$63.55 M
Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio0.7613▲ 60.73%
Total Calls226,200▼ 83.42%
Total Puts172,200▼ 18.04%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %94.34%▲ 3.49%
Total Invested$835.18M▼ 18.41%
Investors Holding179▲ 3.00%

ESG Score

No data

About UroGen Pharma Ltd

CEO: Elizabeth Barrett